Last checked at 9 Jun 2022 07:00
Verici Dx plc
("Verici Dx" or the "Company")
Commercial Team Appointments
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the senior appointments of Grant Harvey and Dr. Windy Tucci as Business Development Director and Medical Science Liaison Director, respectively, with immediate effect.
Grant and Windy join the Verici Dx commercial team ahead of the planned commercial launch of Tuteva™, a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection, which is expected to commence in the latter part of 2022.
Grant Harvey, Business Development Director
Grant joined Verici Dx in June 2022 and brings more than 20 years of cross functional expertise in business development, sales leadership, marketing and training, as well as talent acquisition with a career portfolio of pharmaceuticals, medical services, and diagnostic products.
Prior to partnering with the Verci Dx team, Grant served as a Senior GI Specialty Manager for Exact Sciences, a molecular diagnostics company specializing in the detection of early-stage cancers. Before joining Exact Sciences, Grant served as the Southeast Regional Director with USWorldmeds in the Parkinson's Disease space.
Grant also held numerous senior leadership roles with Horizon Therapeutics, a biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. He also led national sales teams and key account managers in results-driven collaboration.
As director of business development with Fresenius Medical, a German healthcare company which provides kidney dialysis services, he worked with nephrology practices and health systems to overcome marketplace challenges and capitalize on opportunities to improve outcomes and services for dialysis patients.
Grant received his MBA from Elon University and his BS in Marketing from the University of North Carolina Wilmington.
Dr. Windy Tucci, Medical Science Liaison Director
Dr. Windy M. Tucci joined Verici Dx earlier in 2022 with over 15 years of 'hands on' clinical patient care and Pharmaceutical Industry experience in therapeutic areas focusing on Transplant, Gastroenterology, Oncology, Neurology, Cardiology and Nephrology.
She achieved her Doctorate in Pharmacy from the University of Florida, having previously graduated from Roger Williams University.
Prior to Joining Verici Dx, she was the Clinical Lead for the south with Otsuka America Pharmaceutical, and led the Medical Science Liaison team with Exact Sciences where she worked directly with Health Systems, Large Specialty Practices, Healthcare Providers and professional organizations. In these roles, Windy was instrumental in developing new approaches to expand business opportunities, implement sales team expansion and new collaborations, and support pipeline clinical research initiatives.
Sara Barrington, CEO, Verici Dx, said: "We are delighted to welcome Grant and Windy to Verici's commercial team. They bring 35 years of combined industry experience, which will be of great benefit to our team as we launch Tuteva™ commercially later this year."
Enquiries:
Verici Dx | www.vericidx.com |
Sara Barrington, CEO | Via Walbrook PR |
Julian Baines, Chairman | |
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
Aubrey Powell / Kailey Aliyar / Rachel Hayes | |
Walbrook PR Limited | Tel: 020 7933 8780 or vericidx@walbrookpr.com |
Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 |
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.